biologic

Varivax

Varicella Virus Vaccine Live

Loss of exclusivityFebruary 2035projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameVarivax
Active ingredientVaricella Virus Vaccine Live
StrengthNLT 1350PFU/.5ML
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Varivax patent cliff — loss of exclusivity February 2035 | CliffBio